BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37865688)

  • 1. Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
    Petrick JL; Joslin CE; Johnson CE; Camacho TF; Peres LC; Bandera EV; Barnard ME; Beeghly A; Bethea TN; Dempsey LF; Guertin K; Harris HR; Moorman PG; Myers ER; Ochs-Balcom HM; Rosenow W; Setiawan VW; Wu AH; Schildkraut JM; Rosenberg L
    Br J Cancer; 2023 Dec; 129(12):1956-1967. PubMed ID: 37865688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
    DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
    J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study.
    Fournier A; Cairat M; Severi G; Gunter MJ; Rinaldi S; Dossus L
    J Natl Cancer Inst; 2023 Jun; 115(6):671-679. PubMed ID: 36809347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menopausal hormone therapy and cancer risk: An overestimated risk?
    Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
    Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
    Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
    J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.
    Lee AW; Ness RB; Roman LD; Terry KL; Schildkraut JM; Chang-Claude J; Doherty JA; Menon U; Cramer DW; Gayther SA; Risch H; Gentry-Maharaj A; Goodman MT; Modugno F; Eilber U; Moysich KB; Berchuck A; Rossing MA; Jensen A; Wicklund KG; Cushing-Haugen KL; Hogdall E; Rudolph A; Thompson PJ; Wilkens LR; Kjaer SK; Carney ME; Stram DO; Ramus SJ; Wu AH; Pike MC; Pearce CL;
    Obstet Gynecol; 2016 May; 127(5):828-836. PubMed ID: 27054934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Simin J; Tamimi RM; Callens S; Engstrand L; Brusselaers N
    Int J Cancer; 2020 Jul; 147(1):33-44. PubMed ID: 31584190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hysterectomy and risk of epithelial ovarian cancer by histologic type, endometriosis, and menopausal hormone therapy.
    Ring LL; Baandrup L; Zheng G; Gottschau M; Dehlendorff C; Mellemkjær L; Kjaer SK
    Cancer Epidemiol; 2023 Jun; 84():102359. PubMed ID: 37054550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of menopausal hormone therapy on the risk of ovarian cancer: Health Insurance Database in South Korea-based cohort study.
    Yuk JS; Kim M
    Menopause; 2023 May; 30(5):490-496. PubMed ID: 37022299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
    Duus AH; Hannibal CG; Baandrup L; Zheng G; Galanakis M; Maltesen T; Hertzum-Larsen R; Mørch LS; Kjær SK
    Int J Cancer; 2024 Jul; 155(1):19-26. PubMed ID: 38532545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk?
    Rozenberg S; Antoine C; Vandromme J; Fastrez M
    Climacteric; 2015; 18(4):448-52. PubMed ID: 25958744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: The extreme study.
    Baandrup L; Galanakis M; Hannibal CG; Dehlendorff C; Hertzum-Larsen R; Mørch LS; Kjaer SK
    Int J Cancer; 2022 Nov; 151(9):1512-1522. PubMed ID: 35716136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
    Brieger KK; Peterson S; Lee AW; Mukherjee B; Bakulski KM; Alimujiang A; Anton-Culver H; Anglesio MS; Bandera EV; Berchuck A; Bowtell DDL; Chenevix-Trench G; Cho KR; Cramer DW; DeFazio A; Doherty JA; Fortner RT; Garsed DW; Gayther SA; Gentry-Maharaj A; Goode EL; Goodman MT; Harris HR; Høgdall E; Huntsman DG; Shen H; Jensen A; Johnatty SE; Jordan SJ; Kjaer SK; Kupryjanczyk J; Lambrechts D; McLean K; Menon U; Modugno F; Moysich K; Ness R; Ramus SJ; Richardson J; Risch H; Rossing MA; Trabert B; Wentzensen N; Ziogas A; Terry KL; Wu AH; Hanley GE; Pharoah P; Webb PM; Pike MC; Pearce CL;
    Gynecol Oncol; 2020 Sep; 158(3):702-709. PubMed ID: 32641237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menopausal hormone therapy and risk of epithelial ovarian cancer.
    Rossing MA; Cushing-Haugen KL; Wicklund KG; Doherty JA; Weiss NS
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2548-56. PubMed ID: 18086757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy.
    Jordan SJ; Wilson LF; Nagle CM; Green AC; Olsen CM; Bain CJ; Pandeya N; Whiteman DC; Webb PM
    Aust N Z J Public Health; 2015 Oct; 39(5):434-40. PubMed ID: 26437728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal hormones and risk of ovarian cancer.
    Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
    Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.
    Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck A; Danforth KN; Park Y; Brinton LA
    Br J Cancer; 2012 Sep; 107(7):1181-7. PubMed ID: 22929888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Collaborative Group on Hormonal Factors in Breast Cancer
    Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genital Powder Use and Risk of Epithelial Ovarian Cancer in the Ovarian Cancer in Women of African Ancestry Consortium.
    Davis CP; Bandera EV; Bethea TN; Camacho F; Joslin CE; Wu AH; Beeghly-Fadiel A; Moorman PG; Myers ER; Ochs-Balcom HM; Peres LC; Rosenow WT; Setiawan VW; Rosenberg L; Schildkraut JM; Harris HR
    Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1660-1668. PubMed ID: 34155063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
    Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
    J Clin Oncol; 2009 Nov; 27(31):5138-43. PubMed ID: 19752341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.